Sage Open Chronic Dis. 2026 May 20;17:27558428261449178. doi: 10.1177/27558428261449178. eCollection 2026 Jan-Dec.
ABSTRACT
Hidradenitis suppurativa (HS) is a chronic, recurrent, and debilitating inflammatory dermatosis affecting approximately 1% of the population, with a female predominance and substantial psychosocial burden. Clinically, it presents with painful nodules, abscesses, and draining tunnels that often progress to fibrosis and long-term disability. Pathogenesis is multifactorial, encompassing follicular occlusion and rupture, dysbiosis, neutrophil-rich inflammation, and cytokine networks driven by tumor necrosis factor-alpha and interleukin-17 (IL-17), and despite advances, major challenges persist, including phenotypic heterogeneity, diagnostic delays, and the limited durability of monotherapies. This narrative review critically synthesizes evidence on combination strategies in HS following a systematic search of PubMed, Embase, and Cochrane (2009-July 2025), including randomized and nonrandomized trials, cohorts, and case series (⩾10 patients) that evaluated multimodal approaches (antibiotics plus biologics, biologics within surgical pathways, small molecules in combination, laser/light-based therapies, and structured wound care). Outcomes of interest included Hidradenitis Suppurativa Clinical Response, International Hidradenitis Suppurativa Severity Score System (IHS4)/IHS4-55, tunnel resolution, patient-reported measures (Dermatology Life Quality Index), flare frequency, and safety; qualitative synthesis was performed according to Scale for the Assessment of Narrative Review Articles criteria. Antibiotics remain valuable for induction or bridging: clindamycin-rifampicin and multidrug regimens (rifampin-moxifloxacin-metronidazole, ertapenem) yield meaningful but time-limited benefit, optimally used as preparatory steps toward long-term interventions. Biologics form the backbone of durable disease control (adalimumab, secukinumab, bimekizumab), with enhanced outcomes when initiated alongside antibiotics or integrated perioperatively with surgery for tunnel eradication. Among small molecules, Janus kinase inhibitors (e.g., upadacitinib) show promising efficacy; apremilast and IL-36 blockade are exploratory options; sirolimus and conventional immunosuppressants retain niche utility in syndromic or refractory phenotypes. Adjunctive measures, including laser/light therapies, structured wound care, metabolic interventions (notably glucagon-like peptide-1 receptor agonists), smoking cessation, and psychological support, further consolidate disease control, while multidisciplinary care models optimize sequencing, comorbidity management, and recurrence reduction. In conclusion, combination therapy has emerged as the organizing principle of modern HS management: integrating antibiotic induction, biologics for long-term modification, targeted surgery, and adjunctive measures enables deeper and more durable responses. Future priorities include treat-to-target strategies, biomarker-guided selection, antimicrobial stewardship, and pragmatic real-world evaluations to advance toward near-clearance in a broader patient population.
PMID:43034520 | PMC:PMC13768674 | DOI:10.1177/27558428261449178